I am a medical oncologist with more than 20 years of experience in treating patients with a broad spectrum of head and neck malignancies including tumors of the mouth, throat, thyroid, salivary glands, and skin. For these years of service, I was honored to receive Memorial Sloan Kettering’s Willet F. Whitmore Award for Clinical Excellence in 2011.
As Chief of the Head and Neck Oncology Service and Co-Leader of our multidisciplinary disease management team, I work closely with an esteemed and highly coordinated group of medical oncologists, surgeons, radiation oncologists, nurses, and other healthcare professionals to provide our patients with the very best care possible.
Collaborative, multidisciplinary care is especially important for cancers of the head and neck because, generally speaking, treatment not only involves a potentially deadly disease but also issues related to physical appearance, function, and quality of life. An approach that I pioneered with Memorial Sloan Kettering colleagues — known as combined modality organ preservation therapy — uses a combination of chemotherapy and radiation to avoid certain surgical procedures feared by patients such as removal of the voice box, with the intent of preserving function and cosmetic appearance without compromising survival.
My current research is focused on evaluating new forms of chemotherapy called targeted therapies, which selectively kill cancer cells while leaving healthy cells alone. I am also developing customized combined modality therapies based on prognostic risk, and assessing healthcare outcomes.
I have published extensively, previously serving as an associate editor for Clinical Cancer Research and on the editorial board of the Journal of Clinical Oncology, and have been principal investigator on multiple studies.
In addition to being a member of the board of directors for the National Comprehensive Cancer Network, I chair the organization’s head and neck cancer practice guidelines panel. I am also on the board of directors for the International Thyroid Oncology Group, and am co-chair of the Head and Neck Cancer Recurrent/Metastatic Disease Task Force at the National Cancer Institute. Here at Memorial Sloan Kettering, I chair the Committee on Metrics of Care Quality and Outcome.
- Clinical Expertise: Head and Neck Cancers (Larynx/Upper Aerodigestive, Thyroid, Salivary Gland, Skin); Lung Cancer; Genitourinary Malignancies; Larynx/Organ-Preserving Therapies; Immunotherapy; Outcomes Research
- Awards and Honors: New York Magazine Top Doctors (2005-2008; 2010-2016)
- Languages Spoken: English
- Education: MD, University of Pennsylvania School of Medicine
- Residencies: Internal Medicine - Hospital of the University of Pennsylvania
- Fellowships: Clinical Epidemiology/Internal Medicine - Yale-New Haven Hospital/Yale University School of Medicine; Medical Oncology and Hematology - Memorial Sloan Kettering Cancer Center; Medicine - Weill Cornell Medical College
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by David G. Pfister
Clinical Trials Co-Investigated by David G. Pfister
- A Phase I Study of Dabrafenib plus Lapatinib to Treat Inoperable Thyroid Cancers with Abnormal BRAF
- A Phase II Study of Lenvatinib for Patients with Anaplastic Thyroid Cancer
- A Phase II Study of Lenvatinib in Patients with Adenoid Cystic Carcinoma
- A Phase II Study of Radioactive Iodine (RAI) with Selumetinib or a Placebo to Treat RAI-Avid Recurrent or Metastatic Thyroid Cancer
- A Phase II Study of REGN2810 Immunotherapy for Patients with Advanced Squamous Cell Cancer of the Skin
- A Phase II Study of Sorafenib Alone and with Everolimus in Patients with Hurthle Cell Thyroid Cancer that Does Not Response to Radioactive Iodine Therapy
- A Phase II Study of Tipifarnib in Patients with Advanced Solid Tumors Containing HRAS Mutations
- A Phase II Study of Trametinib to Enhance Radioactive Iodine (RAI) Uptake in Patients with RAI-Resistant Recurrent or Metastatic Thyroid Cancer
- A Phase III Study of MEDI4736 with and without Tremelimumab versus Standard of Care in Recurrent/Metastatic Head and Neck Cancer
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more